Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Thursday, September 25, 2025
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Roche plans to become top 3 obesity player as CT-388 enters trial

September 25, 2025
in News
Reading Time: 3 mins read
A A
Roche plans to become top 3 obesity player as CT-388 enters trial
0
SHARES
ShareShareShareShareShare

READ ALSO

Nvidia OpenAI investment in cash mostly used to lease Nvidia chips

Lithium Americas LAC Trump government stake Canada

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland.

Sedat Suna | Getty Images News | Getty Images

Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to a late-stage trial.

“I want you to know that I am serious about this goal,” Teresa Graham, CEO of Roche Pharmaceuticals, told investors and analysts on at Roche’s Pharma Day in London on Monday.

“We know how to break into new markets,” she added.

The drugmaker said earlier this week that its CT-388 weight loss injection was entering a phase III trial — the final stage before a company can seek regulatory approval — marking the latest development in Roche’s nascent but fast-growing pipeline of treatments for obesity and related conditions.

Roche does not currently have any approved obesity drugs on the market, but Graham said the company was aiming for launch across its suite of treatments by 2030.

That includes the closely watched Petrelintide drug candidate, which Roche is currently co-developing and co-commercializing as part of a $5.3 billion partnership with Danish biotech Zealand Pharma.

“I think we’re on track to that,” Manu Chakravarthy, vice president and global head of cardiovascular, renal and metabolism product development, told CNBC of the timeline for Petrelintide.

“We’re very much committed to trying to pull that [timeline] in as much as possible,” he added.

Petrelintide, a nascent form of treatment known as an amylin analog, adds to Roche’s existing GLP-1 offering including CT-388 and once-daily oral candidate CT-996, which were both acquired as part of Roche’s first foray into the obesity market with the purchase in late 2023 of U.S. biotech Carmot Therapeutics.

Obesity drug market

The company further bolstered its offering last week with a deal to buy U.S. biotech company 89bio, joining competitors in developing new liver disease treatments to complement weight loss drugs.

Graham told investors she was confident that Roche’s growing suite of drug candidates would help bolster its chances of success in the increasingly competitive weight-loss drug market.

Yihan Li, pharma analyst at Barclays, said Roche’s goal of becoming a top three player was “potentially achievable” due to their broad pipeline of obesity assets, but noted that next year would be a “big year” for their trial readouts.

“More importantly, the obesity market is only a duopoly currently. So it will be a question mark how big the gap will be between Roche vs. Novo/LLY,” she wrote in emailed comments, adding that other competitor treatments were likely to come to market ahead of Roche.

It comes as rivals Eli Lilly and Novo Nordisk have been racing to get their obesity pills to market, as they seek to expand their offering amid booming demand for their GLP-1 treatments. Both companies are also exploring amylin analog candidates as well as other experimental treatments.

Already the pair dominate the obesity drug market, even as competition from copycat compounded pharmacies has grown.

Roche plans to become top 3 obesity player as CT-388 enters trial

Nevertheless, Graham suggested that newer market entrants could learn important lessons from the first round of obesity treatments. In particular, she said “next-generation” drugs should address unmet needs around tolerability, weight maintenance, treatment of comorbidities and lean muscle loss.

“Our differentiation relies on having that breadth of options,” she said. “We can cover the breadth of this unmet need completely.”

“If you don’t have portfolio of solutions, that’s what makes it limiting,” Chakravarthy added.

Credit: Source link

ShareTweetSendSharePin
Previous Post

Tommy Fleetwood knows fan-favorite status goes away at Ryder Cup

Related Posts

Nvidia OpenAI investment in cash mostly used to lease Nvidia chips
News

Nvidia OpenAI investment in cash mostly used to lease Nvidia chips

September 25, 2025
Lithium Americas LAC Trump government stake Canada
News

Lithium Americas LAC Trump government stake Canada

September 24, 2025
Defense stocks rally as Trump says Kyiv can win back all of Ukraine
News

Defense stocks rally as Trump says Kyiv can win back all of Ukraine

September 24, 2025
Alibaba shares jump 9% in U.S. premarket after CEO unveils plans to boost AI spending
News

Alibaba shares jump 9% in U.S. premarket after CEO unveils plans to boost AI spending

September 24, 2025
How Britain’s startup sector is evolving
News

How Britain’s startup sector is evolving

September 24, 2025
TikTok tops the trade talk
News

TikTok tops the trade talk

September 24, 2025

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

‘Love Story’ for markets: Travis Kelce unveils American Eagle collection right after Taylor Swift engagement

‘Love Story’ for markets: Travis Kelce unveils American Eagle collection right after Taylor Swift engagement

August 28, 2025
Behind the smiles with Putin, Modi and Xi at China summit

Behind the smiles with Putin, Modi and Xi at China summit

September 1, 2025
Lithium Americas LAC Trump government stake Canada

Lithium Americas LAC Trump government stake Canada

September 24, 2025
What the CEOs of Walmart, Best Buy, Home Depot, and others say about the nervous consumer

What the CEOs of Walmart, Best Buy, Home Depot, and others say about the nervous consumer

September 2, 2025
Alibaba leads 0 million investment in Chinese humanoid robot startup

Alibaba leads $100 million investment in Chinese humanoid robot startup

September 8, 2025
Pick up Apple’s 25W MagSafe charger while it’s down to only

Pick up Apple’s 25W MagSafe charger while it’s down to only $35

September 20, 2025
Nestlé fired its scandal-clad CEO without a payout—a ‘really unusual’ move, expert says

Nestlé fired its scandal-clad CEO without a payout—a ‘really unusual’ move, expert says

September 3, 2025

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Roche plans to become top 3 obesity player as CT-388 enters trial
  • Tommy Fleetwood knows fan-favorite status goes away at Ryder Cup
  • Nvidia OpenAI investment in cash mostly used to lease Nvidia chips
  • Success of deadline additions came with help from Yankees’ personal touch

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In